On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
Pfizer Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.
More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.
One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!
The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.
New evidence of the power of the multi-billion dollar impotence drugs. A study just out in the peer-reviewed "British Medical Journal" says that the elderly are having sex more often, possibly due to the popular pills for erectile dysfunction.
Drug developer Eli Lilly will buy SGX Pharmaceuticals for about $64 million in cash in an effort to expand its drug discovery efforts, the companies said Tuesday.
On another ugly day for the stock markets, beaten down shares of Dow component Merck rallied. The stock started picking up steam after the news broke late this morning that its late-stage experimental migraine headache drug essentially works just as well as an existing drug, but with fewer side effects.
Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days.
As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...
Japanese drug maker Daiichi Sankyo will pay up to $4.6 billion for control of India's Ranbaxy Laboratories, the latest in a string of global health deals as firms look to bulk up and diversify to fend off aggressive rivals.
Despite the Dow's slight uptick, inflation and credit concerns continued to weigh heavily on stocks Tuesday.
First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.
Eli Lilly, Amylin and Alkermes, partners on the first-ever once-a-week drug for diabetes, announced that patients saw their blood sugar go down by two percent and their weight drop an average nine-and-a-half pounds after one year on the experimental treatment.
Amylin fell more than 8% Monday after data from an important diabetes meeting sparked concern about competition to the drug Byetta. How to trade?
Gary Anderson thinks investors should look beyond America's borders for their stock-market winnings.
We are covering the ADA meeting today and tomorrow because most of the major data came out over the weekend or is coming out later today. Or so we thought.
"You continue--day after day--to knock the company at every opportunity. I understand you had a difficult relationship with the CEO before, but you shouldn't hold a grudge against the company for it..."
Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold.
The American Society of Clinical Oncology annual meeting, which starts today in Chicago, couldn't get any bigger for ImClone Systems and its Erbitux partners Bristol-Myers Squibb and the German Merck (no relation to the U.S.-based Merck).